1.
Blood
; 141(14): 1659-1665, 2023 04 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36669155
RESUMO
Within the first months of the COVID-19 vaccination campaign, previously healthy recipients who developed severe thrombosis (often cerebral and/or splanchnic vasculature) and thrombocytopenia typically after adenoviral vector-based vaccination were identified. Similarities between this syndrome, vaccine-induced immune thrombotic thrombocytopenia (VITT), and heparin-induced thrombocytopenia prompted recognition of the role of antiplatelet factor 4 (PF4) antibodies and management strategies based on IV immunoglobulin and nonheparin anticoagulants, which improved outcome. We update current understanding of VITT and potential involvement of anti-PF4 antibodies in thrombotic disorders.
Assuntos
COVID-19 , Púrpura Trombocitopênica Idiopática , Trombocitopenia , Trombose , Vacinas , Humanos , Vacinas contra COVID-19/efeitos adversos , Púrpura Trombocitopênica Idiopática/induzido quimicamente , Púrpura Trombocitopênica Idiopática/terapia , Trombocitopenia/induzido quimicamente , Trombose/etiologia , Fator Plaquetário 4
2.
Thromb Haemost
; 88(6): 888-9, 2002 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-12529733